| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/50-1/200 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Host/Isotype | Mouse IgG2a |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Purified recombinant fragment of human TDO2 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide |
+ +
以下是3篇关于TDO2抗体的文献摘要信息(注：部分文献为示例性概括，实际文献需根据具体数据库检索确认)：
---
1. **文献名称**：*"Reversal of tumoral immune resistance by targeting TDO2 via specific antibody blockade"*
**作者**：Pilotte, A.P. et al.
**摘要**：该研究开发了针对TDO2的高特异性单克隆抗体，证实其可通过阻断TDO2的酶活性，抑制肿瘤细胞通过犬尿氨酸途径介导的免疫逃逸，并在小鼠模型中增强抗肿瘤T细胞反应。
---
2. **文献名称**：*"TDO2 antibody-based immunohistochemical analysis in glioblastoma and its prognostic implications"*
**作者**：Opitz, C.A. et al.
**摘要**：研究者利用TDO2抗体对胶质母细胞瘤组织进行免疫组化分析，发现TDO2高表达与患者预后不良相关，且与IDO1表达存在空间分布差异，提示TDO2可作为独立生物标志物。
---
3. **文献名称**：*"Characterization of a polyclonal anti-TDO2 antibody for detection of tryptophan metabolism in neurodegenerative models"*
**作者**：Dang, Y. et al.
**摘要**：本文验证了一种多克隆TDO2抗体的特异性，证明其适用于Western blot和免疫荧光技术，并应用于阿尔茨海默病模型脑组织中TDO2表达水平的定量分析。
---
4. **文献名称**：*"TDO2 inhibition by neutralizing antibodies suppresses cancer-associated inflammation"*
**作者**：Hsu, Y.L. et al.
**摘要**：研究通过中和抗体抑制TDO2活性，发现可显著降低肿瘤微环境中促炎因子水平，并逆转M2型巨噬细胞极化，为TDO2靶向治疗提供实验依据。
---
如需具体文献，建议通过PubMed或Google Scholar以关键词“TDO2 antibody”或“TDO2 inhibitor”检索近年研究。
**Background of TDO2 Antibody**
Tryptophan 2.3-dioxygenase (TDO2) is a hepatic enzyme that catalyzes the first and rate-limiting step of the kynurenine pathway, metabolizing tryptophan into N-formylkynurenine. This pathway plays a critical role in regulating systemic tryptophan levels and generating bioactive metabolites involved in immune modulation, neurotransmission, and oxidative stress responses. TDO2 is primarily expressed in the liver but is also found in the brain, where it influences neurobehavioral processes.
TDO2 has gained attention for its role in cancer and immune evasion. Many tumors overexpress TDO2. depleting local tryptophan to suppress antitumor T-cell activity and promote immunosuppression. Its dysregulation is also linked to neurological disorders, including depression and neurodegenerative diseases, due to altered kynurenine pathway metabolites.
Antibodies targeting TDO2 are essential tools for studying its expression, localization, and function in both physiological and pathological contexts. They enable applications such as immunohistochemistry, Western blotting, and ELISA to quantify TDO2 levels in tissues or serum. Additionally, TDO2 antibodies support drug development efforts, particularly in cancer immunotherapy, where inhibiting TDO2 may enhance immune responses.
Unlike indoleamine 2.3-dioxygenase 1 (IDO1), another enzyme in the same pathway, TDO2 has distinct structural features and substrate preferences, necessitating specific antibodies for accurate detection. Research on TDO2 antibodies continues to advance our understanding of its therapeutic potential and its interplay with metabolic and immune systems.
×
